While eye drops are often a helpful treatment mechanism that deliver necessary medications to the ocular surface, they can also present challenges for some patients.
The number of people in the United States using eye drops once or more per day increased nearly 10% from 2011 to 2020. Experts expect this number to continue growing as more Americans age and develop ocular conditions treated with eye drops.
Being diagnosed with glaucoma is often a life-changing event. With no current cure, the disease, which results in damages to the optic nerve causing irreversible vision loss, is expected to affect up to 112 million people worldwide by 2040.
Research Glaucoma Artificial Intelligence (AI)
Large language models (LLMs), such as ChatGPT, have skyrocketed in popularity in the last year due to their ability to utilize vast amounts of information, but could they be used to diagnose ocular disease?
Innovation Patient Care Glaucoma
About once a month, Deidre St. Peter, MD, assistant professor of ophthalmology at the University of Colorado School of Medicine, performs a XEN Gel Stent surgery, implanting a tiny tube-like structure into the eye to reduce pressure and prevent vision loss associated with open-angle glaucoma.
Ram Nagaraj, PhD, professor in the University of Colorado Department of Ophthalmology, envisions a future where ophthalmologists can prevent vision loss associated with glaucoma, the second leading cause of blindness in the world.
Innovation Clinical Research Cataracts Glaucoma
A new drug delivery platform developed by Malik Y. Kahook, MD, professor of ophthalmology and the Slater Family Endowed Chair in Ophthalmology at the University of Colorado School of Medicine, shows promise for the future of glaucoma care after six months of follow up in the first human study.
Awareness Glaucoma Diabetic retinopathy Equity Diversity and Inclusion
Although Black Americans are the second-largest minority population in the United States, they remain underrepresented in vision health research. They also carry the highest burden of eye disease ranging from general visual impairment to glaucoma, diabetic retinopathy, and blindness.
Patient Care Advancement Cataracts Glaucoma
Philip Tarlow’s inspiration to pursue art was sparked at an early age. He recalls a kindergarten teacher noticing his fascination with construction workers, which ultimately became the subject matter of his creations 30 years later.
Procedures to alleviate eye pressure associated with blinding diseases such as glaucoma date back over a century. Although glaucoma, a condition that damages the eye’s optic nerve, allows for a number of treatment options prior to surgery, including drops and lasers, research has shown traditional surgical techniques could result in higher risks of vision complications, longer recovery times, and higher associated costs. Identifying this disconnect, Malik Y. Kahook, MD, professor of ophthalmology and the Slater Family Endowed Chair in Ophthalmology at the University of Colorado School of Medicine, sought out a more accessible and practical solution to propel glaucoma treatment into the 21st century.
HCP Live
July 26, 2024
Maternal asthma could increase the likelihood of a blinding eye disease in premature infants, according to a new study by investigator led by Zafar Gill, MD, a vitreoretinal diseases and surgery fellow in the Department of Ophthalmology.
Ophthalmology Times
July 22, 2024
Riaz Qureshi, PhD, an assistant professor of ophthalmology at the University of Colorado School of Medicine, recently published a paper in Annals of Internal Medicine that features an international team of researchers that has established a framework providing guidance to authors, peer reviewers, and editors to rectify spin of harms in systematic review.
Cosmos Magazine
July 22, 2024
An international group of medical researchers led by Riaz Qureshi, PhD, assistant professor of ophthalmology, is calling for a better understanding of “spin” in research papers.
CPR
July 19, 2024
“I think their position is ridiculous and negligent,” said Dr. Michael Puente, a pediatric ophthalmologist at the University of Colorado and Children’s Hospital Colorado in Aurora. “It’s ridiculous that a policy still exists with no scientific evidence to support it.”
Kara Mason
